

CORRECTION

Open Access



Correction to: CART cells are prone to Fas- and DR5-mediated cell death

Benjamin O. Tschumi¹, Nina Dumauthioz¹, Bastien Marti¹, Lianjun Zhang¹, Evipridis Lanitis^{2,3}, Melita Irving^{2,3}, Pascal Schneider⁴, Jean-Pierre Mach⁴, George Coukos^{2,3}, Pedro Romero¹ and Alena Donda^{1*}

Correction

After publication of this article [1], it was noticed that 3 authors were missed from the author list. These authors are Evipridis Lanitis, Melita Irving and George Coukos. The correct author list can be seen above and updated Competing Interests, Authors' Contributions and Acknowledgements can be seen below.

Acknowledgements

We are grateful to P. Reichenbach for sharing his expertise in DNA cloning strategies. Special thanks to Prof. M. Thome for sharing her expertise in the field of T cell signalling.

Authors' contributions

AD and BT designed and developed the study. BT, ND, BM and LZ performed the experiments, acquired and analyzed the data. E.L. has set up the protocol of transduction of murine primary lymphocytes. EL, MI and GC contributed to the conception, experimental design and analysis of results. PS shared his expertise on programmed cell death and provided essential reagents. AD, BT, LZ, PR and JPM wrote the manuscript. All authors read and approved the final manuscript.

Competing interests

All co-authors declare that they have no competing interests.

Author details

¹Department of Fundamental Oncology, Translational Tumor Immunology Group, Lausanne, Switzerland. ²Department of Oncology, University Hospital of Lausanne, Lausanne, Switzerland. ³Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland. ⁴Department of Biochemistry, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.

Received: 14 September 2018 Accepted: 14 September 2018

Published online: 25 September 2018

Reference

1. Tschumi BO, Dumauthioz N, Marti B, Zhang L, Schneider P, Mach J-P, et al. CART cells are prone to Fas- and DR5-mediated cell death. *J Immuno Cancer*. 2018;6:71 <https://doi.org/10.1186/s40425-018-0385-z>.

* Correspondence: Alena.donda@unil.ch

¹Department of Fundamental Oncology, Translational Tumor Immunology Group, Lausanne, Switzerland

Full list of author information is available at the end of the article

